{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pred+Forte&page=6",
    "query": {
      "intervention": "Pred Forte",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 729,
    "total_pages": 73,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pred+Forte&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pred+Forte&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T20:05:56.737Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06561035",
      "title": "Reduce Opiate Exposure With ACL Surgery",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anterior Cruciate Ligament Injuries"
      ],
      "interventions": [
        {
          "name": "Opiate Sparing",
          "type": "DRUG"
        },
        {
          "name": "Opiate Based",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Campbell Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "14 Years to 85 Years"
      },
      "enrollment_count": 56,
      "start_date": "2024-09-01",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-18T20:05:56.737Z",
      "location_count": 3,
      "location_summary": "Skokie, Illinois • Cincinnati, Ohio • Memphis, Tennessee",
      "locations": [
        {
          "city": "Skokie",
          "state": "Illinois"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06561035"
    },
    {
      "nct_id": "NCT00393367",
      "title": "Budesonide Inhalation Suspension for Acute Asthma in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma",
        "Acute Asthma",
        "Reactive Airway Exacerbation"
      ],
      "interventions": [
        {
          "name": "Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone, prednisone, or methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Albuterol, ipratropium bromide",
          "type": "DRUG"
        },
        {
          "name": "Ipratropium bromide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 179,
      "start_date": "2006-12",
      "completion_date": "2007-11",
      "has_results": true,
      "last_update_posted_date": "2012-08-10",
      "last_synced_at": "2026-10-18T20:05:56.737Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00393367"
    },
    {
      "nct_id": "NCT02229136",
      "title": "Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stomatitis",
        "Oral Mucositis",
        "Neoplasm of the Breast",
        "Malignant Tumor of Breast"
      ],
      "interventions": [
        {
          "name": "Miracle Mouthwash Plus Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Oncology Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 104,
      "start_date": "2014-09-04",
      "completion_date": "2022-11",
      "has_results": false,
      "last_update_posted_date": "2022-12-01",
      "last_synced_at": "2026-10-18T20:05:56.737Z",
      "location_count": 1,
      "location_summary": "US, Texas",
      "locations": [
        {
          "city": "US",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02229136"
    },
    {
      "nct_id": "NCT00003960",
      "title": "Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "in vitro-treated bone marrow transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "1998-04",
      "completion_date": "2001-09",
      "has_results": false,
      "last_update_posted_date": "2014-05-02",
      "last_synced_at": "2026-10-18T20:05:56.737Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Columbia, South Carolina",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Columbia",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003960"
    },
    {
      "nct_id": "NCT06717347",
      "title": "A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Zilovertamab vedotin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab Biosimilar",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Rescue medication",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1046,
      "start_date": "2025-01-27",
      "completion_date": "2032-03-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-18T20:05:56.737Z",
      "location_count": 59,
      "location_summary": "Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06717347"
    },
    {
      "nct_id": "NCT06489626",
      "title": "The Effect of a Methylprednisolone Taper on Outcomes Following Total Knee Arthroplasty",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Arthritis Knee",
        "Knee Osteoarthritis",
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "Methylprednisolone 4 milligram Tab",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "F. Johannes Plate",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-11-01",
      "completion_date": "2027-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-10-18T20:05:56.737Z",
      "location_count": 2,
      "location_summary": "Monroeville, Pennsylvania • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Monroeville",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06489626"
    },
    {
      "nct_id": "NCT00519285",
      "title": "Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostatic Neoplasms",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for aflibercept)",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Prednisone or Prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1224,
      "start_date": "2007-08",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2016-07-22",
      "last_synced_at": "2026-10-18T20:05:56.737Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00519285"
    },
    {
      "nct_id": "NCT01086540",
      "title": "Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis-Associated PAH"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "CMRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "acetaminophen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DIAGNOSTIC_TEST",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 57,
      "start_date": "2011-06-24",
      "completion_date": "2019-12-15",
      "has_results": true,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-10-18T20:05:56.737Z",
      "location_count": 17,
      "location_summary": "Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01086540"
    },
    {
      "nct_id": "NCT00521989",
      "title": "CRx-102 Osteoarthritis Multicenter Evaluation Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Knee Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "CRx-102 (2.7/90)",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "CRx-102 (2.7/180)",
          "type": "DRUG"
        },
        {
          "name": "CRx-102 (2.7/360)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zalicus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 279,
      "start_date": "2007-08",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2014-04-29",
      "last_synced_at": "2026-10-18T20:05:56.737Z",
      "location_count": 57,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 54 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00521989"
    },
    {
      "nct_id": "NCT03072238",
      "title": "Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Prednisone/Prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1101,
      "start_date": "2017-06-30",
      "completion_date": "2024-04-24",
      "has_results": true,
      "last_update_posted_date": "2025-06-06",
      "last_synced_at": "2026-10-18T20:05:56.737Z",
      "location_count": 32,
      "location_summary": "Chandler, Arizona • Scottsdale, Arizona • Duarte, California + 28 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03072238"
    }
  ]
}